Smouldering multiple sclerosis: the ‘real MS’
Open accessThe DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Abstract
Using a philosophical approach or deductive reasoning, we challenge the dominant clinico-radiological worldview that defines multiple sclerosis (MS) as a focal inflammatory disease of the central nervous system (CNS). We provide a range of evidence to argue that the ‘real MS’ is in fact driven primarily by a smouldering pathological disease process. In natural history studies and clinical trials, relapses and focal activity revealed by magnetic resonance imaging (MRI) in MS patients on placebo or on disease-modifying therapies (DMTs) were found to be poor predictors of long-term disease evolution and were dissociated from disability outcomes. In addition, the progressive accumulation of disability in MS can occur independently of relapse activity from early in the disease course. This scenario is underpinned by a more diffuse smouldering pathological process that may affect the entire CNS. Many putative pathological drivers of smouldering MS can be potentially modified by specific therapeutic strategies, an approach that may have major implications for the management of MS patients. We hypothesise that therapeutically targeting a state of ‘no evident inflammatory disease activity’ (NEIDA) cannot sufficiently prevent disability accumulation in MS, meaning that treatment should also focus on other brain and spinal cord pathological processes contributing to the slow loss of neurological function. This should also be complemented with a holistic approach to the management of other systemic disease processes that have been shown to worsen MS outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Alpha-lipoic acid as a biological antioxidant
Packer, L., Witt, E. H., & Tritschler, H. J. (1995) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(95)00017-r · Cited by 1,979
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905
Self-citationCortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
The effect of age on the non-haemin iron in the human brain
Hallgren, B., & Sourander, P. (1958) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1958.tb12607.x · Cited by 1,427
Relapses and Progression of Disability in Multiple Sclerosis
Confavreux, C., Vukusic, S., Moreau, T., & Adeleine, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432001 · Cited by 1,309
Pathological mechanisms in progressive multiple sclerosis
Mahad, D. H., Trapp, B. D., & Lassmann, H. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70256-x · Cited by 1,137
Confavreux, C. (2003) · Brain · doi:10.1093/brain/awg081 · Cited by 996
Natural history of multiple sclerosis: a unifying concept
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awl007 · Cited by 905
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Howell, O. W., Reeves, C. A., Nicholas, R., Carassiti, D., Radotra, B., Gentleman, S. M., Serafini, B., Aloisi, F., Roncaroli, F., Magliozzi, R., et al. (2011) · Brain · doi:10.1093/brain/awr182 · Cited by 858
Kuhlmann, T. (2002) · Brain · doi:10.1093/brain/awf235 · Cited by 775
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Cohen, J. A., Comi, G., Correale, J., Coyle, P. K., Cross, A. H., de Seze, J., Leppert, D., Montalban, X., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917246 · Cited by 734
Frischer, J. M., Weigand, S. D., Guo, Y., Kale, N., Parisi, J. E., Pirko, I., Mandrekar, J., Bramow, S., Metz, I., Brück, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24497 · Cited by 728
Scalfari, A., Neuhaus, A., Degenhardt, A., Rice, G. P., Muraro, P. A., Daumer, M., & Ebers, G. C. (2010) · Brain · doi:10.1093/brain/awq118 · Cited by 711
Self-citationPathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis
Lassmann, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03116 · Cited by 663
Kappos, L., Wolinsky, J. S., Giovannoni, G., Arnold, D. L., Wang, Q., Bernasconi, C., Model, F., Koendgen, H., Manfrini, M., Belachew, S., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1568 · Cited by 658
Self-citationVirtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis
Trapp, B. D., & Stys, P. K. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70043-2 · Cited by 621
Evidence for a two-stage disability progression in multiple sclerosis
Leray, E., Yaouanq, J., Le Page, E., Coustans, M., Laplaud, D., Oger, J., & Edan, G. (2010) · Brain · doi:10.1093/brain/awq076 · Cited by 596
CLINICAL VIRAL INFECTIONS AND MULTIPLE SCLEROSIS
SIBLEY, W. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92801-6 · Cited by 594
Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo
Absinta, M., Sati, P., Masuzzo, F., Nair, G., Sethi, V., Kolb, H., Ohayon, J., Wu, T., Cortese, I. C. M., & Reich, D. S. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2399 · Cited by 534
Age at disability milestones in multiple sclerosis
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awh714 · Cited by 525
Iron and neurodegeneration in the multiple sclerosis brain
Hametner, S., Wimmer, I., Haider, L., Pfeifenbring, S., Brück, W., & Lassmann, H. (2013) · Annals of Neurology · doi:10.1002/ana.23974 · Cited by 519
Coles, A. J., Cox, A., Page, E., Jones, J., Trip, S. A., Deans, J., Seaman, S., Miller, D. H., Hale, G., Waldmann, H., et al. (2006) · Journal of Neurology · doi:10.1007/s00415-005-0934-5 · Cited by 506
Will the real multiple sclerosis please stand up?
Stys, P. K., Zamponi, G. W., van Minnen, J., & Geurts, J. J. G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3275 · Cited by 475
Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging
Dal-Bianco, A., Grabner, G., Kronnerwetter, C., Weber, M., Höftberger, R., Berger, T., Auff, E., Leutmezer, F., Trattnig, S., Lassmann, H., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1636-z · Cited by 463
Immunopathology of secondary‐progressive multiple sclerosis
Prineas, J. W., Kwon, E. E., Cho, E., Sharer, L. R., Barnett, M. H., Oleszak, E. L., Hoffman, B., & Morgan, B. P. (2001) · Annals of Neurology · doi:10.1002/ana.1255 · Cited by 453
Prospective study on the relationship between infections and multiple sclerosis exacerbations
Buljevac, D., Flach, H. Z., Hop, W. C. J., Hijdra, D., Laman, J. D., Savelkoul, H. F. J., van der Meché, F. G. A., van Doorn, P. A., & Hintzen, R. Q. (2002) · Brain · doi:10.1093/brain/awf098 · Cited by 427
Mitochondrial defects in acute multiple sclerosis lesions
Mahad, D., Ziabreva, I., Lassmann, H., & Turnbull, D. (2008) · Brain · doi:10.1093/brain/awn105 · Cited by 406
Progression of regional grey matter atrophy in multiple sclerosis
Eshaghi, A., Marinescu, R. V., Young, A. L., Firth, N. C., Prados, F., Jorge Cardoso, M., Tur, C., De Angelis, F., Cawley, N., Brownlee, W. J., et al. (2018) · Brain · doi:10.1093/brain/awy088 · Cited by 372
Luchetti, S., Fransen, N. L., van Eden, C. G., Ramaglia, V., Mason, M., & Huitinga, I. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1818-y · Cited by 355
Treatment of multiple sclerosis — success from bench to bedside
Tintore, M., Vidal-Jordana, A., & Sastre-Garriga, J. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0082-z · Cited by 343
Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions
Absinta, M., Sati, P., Schindler, M., Leibovitch, E. C., Ohayon, J., Wu, T., Meani, A., Filippi, M., Jacobson, S., Cortese, I. C. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86198 · Cited by 327
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
De Stefano, N., Giorgio, A., Battaglini, M., Rovaris, M., Sormani, M. P., Barkhof, F., Korteweg, T., Enzinger, C., Fazekas, F., Calabrese, M., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e24136 · Cited by 321
Tourbah, A., Lebrun-Frenay, C., Edan, G., Clanet, M., Papeix, C., Vukusic, S., De Sèze, J., Debouverie, M., Gout, O., Clavelou, P., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516667568 · Cited by 302
Measurement and clinical effect of grey matter pathology in multiple sclerosis
Geurts, J. J., Calabrese, M., Fisher, E., & Rudick, R. A. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70230-2 · Cited by 298
Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity?
Marik, C., Felts, P. A., Bauer, J., Lassmann, H., & Smith, K. J. (2007) · Brain · doi:10.1093/brain/awm236 · Cited by 292
Human Endogenous Retroviruses in Neurological Diseases
Küry, P., Nath, A., Créange, A., Dolei, A., Marche, P., Gold, J., Giovannoni, G., Hartung, H.-P., & Perron, H. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.02.007 · Cited by 288
Self-citationDe Groot, C. J. A. (2001) · Brain · doi:10.1093/brain/124.8.1635 · Cited by 285
Chard, D. T. (2002) · Brain · doi:10.1093/brain/awf240 · Cited by 280
Neuroprotection and repair in multiple sclerosis
Franklin, R. J. M., ffrench-Constant, C., Edgar, J. M., & Smith, K. J. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.200 · Cited by 278
Influence of infection on exacerbations of multiple sclerosis
Panitch, H. S. (1994) · Annals of Neurology · doi:10.1002/ana.410360709 · Cited by 276
on behalf of the MAGNIMS study group, Sastre-Garriga, J., Pareto, D., Battaglini, M., Rocca, M. A., Ciccarelli, O., Enzinger, C., Wuerfel, J., Sormani, M. P., Barkhof, F., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0314-x · Cited by 273
Self-citationViral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study
Andersen, O., Lygner, P.-E., Bergstr�m, T., Andersson, M., & Vablne, A. (1993) · Journal of Neurology · doi:10.1007/bf00867354 · Cited by 265
YOUL, B. D., TURANO, G., MILLER, D. H., TOWELL, A. D., MACMANUS, D. G., MOORE, S. G., JONES, S. J., BARRETT, G., KENDALL, B. E., MOSELEY, I. F., et al. (1991) · Brain · doi:10.1093/brain/114.6.2437 · Cited by 259
Comorbidity in multiple sclerosis: implications for patient care
Marrie, R. A. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.33 · Cited by 248
Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging
Ciccarelli, O., Barkhof, F., Bodini, B., Stefano, N. D., Golay, X., Nicolay, K., Pelletier, D., Pouwels, P. J. W., Smith, S. A., Wheeler-Kingshott, C. A. M., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70101-2 · Cited by 241
Self-citationImpact of multiple sclerosis relapses on progression diminishes with time
Tremlett, H., Yousefi, M., Devonshire, V., Rieckmann, P., & Zhao, Y. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c1e44f · Cited by 221
Perron, H., Jouvin-Marche, E., Michel, M., Ounanian-Paraz, A., Camelo, S., Dumon, A., Jolivet-Reynaud, C., Marcel, F., Souillet, Y., Borel, E., et al. (2001) · Virology · doi:10.1006/viro.2001.1045 · Cited by 193
Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis
Jokubaitis, V. G., Spelman, T., Kalincik, T., Lorscheider, J., Havrdova, E., Horakova, D., Duquette, P., Girard, M., Prat, A., Izquierdo, G., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24682 · Cited by 191
Self-citationThe natural history of multiple sclerosis: a geographically based study
Kremenchutzky, M., Cottrell, D., Rice, G., Hader, W., Baskerville, J., Koopman, W., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.10.1941 · Cited by 186
Giovannoni, G., Tomic, D., Bright, J. R., & Havrdová, E. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517703193 · Cited by 184
Self-citationPredictors of long‐term outcome in multiple sclerosis patients treated with interferon beta
Bermel, R. A., You, X., Foulds, P., Hyde, R., Simon, J. H., Fisher, E., & Rudick, R. A. (2013) · Annals of Neurology · doi:10.1002/ana.23758 · Cited by 180
Rissanen, E., Tuisku, J., Rokka, J., Paavilainen, T., Parkkola, R., Rinne, J. O., & Airas, L. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.131698 · Cited by 171
Self-citationPreactive lesions in multiple sclerosis
van der Valk, P., & Amor, S. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32832b4c76 · Cited by 156
Cadavid, D., Cohen, J. A., Freedman, M. S., Goldman, M. D., Hartung, H.-P., Havrdová, E., Jeffery, D., Kapoor, R., Miller, A., Sellebjerg, F. T., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516638941 · Cited by 152
Linker, R., Gold, R., & Luhder, F. (2009) · Critical Reviews™ in Immunology · doi:10.1615/critrevimmunol.v29.i1.20 · Cited by 150
Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis
Sucksdorff, M., Matilainen, M., Tuisku, J., Polvinen, E., Vuorimaa, A., Rokka, J., Nylund, M., Rissanen, E., & Airas, L. (2020) · Brain · doi:10.1093/brain/awaa275 · Cited by 142
Self-citationNeurological deficits caused by tissue hypoxia in neuroinflammatory disease
Davies, A. L., Desai, R. A., Bloomfield, P. S., McIntosh, P. R., Chapple, K. J., Linington, C., Fairless, R., Diem, R., Kasti, M., Murphy, M. P., et al. (2013) · Annals of Neurology · doi:10.1002/ana.24006 · Cited by 142
Lesion stage-dependent causes for impaired remyelination in MS
Heß, K., Starost, L., Kieran, N. W., Thomas, C., Vincenten, M. C. J., Antel, J., Martino, G., Huitinga, I., Healy, L., & Kuhlmann, T. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02189-9 · Cited by 137
Pathogenic implications of distinct patterns of iron and zinc in chronic MS lesions
Popescu, B. F., Frischer, J. M., Webb, S. M., Tham, M., Adiele, R. C., Robinson, C. A., Fitz-Gibbon, P. D., Weigand, S. D., Metz, I., Nehzati, S., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1696-8 · Cited by 136
Identification of Chronic Active Multiple Sclerosis Lesions on 3T MRI
Absinta, M., Sati, P., Fechner, A., Schindler, M. K., Nair, G., & Reich, D. S. (2018) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5660 · Cited by 131
Spinal Cord Atrophy in Multiple Sclerosis: A Systematic Review and Meta‐Analysis
Casserly, C. S., Seyman, E., Leon, P. A., Guenette, M. D., Lyons, C. E., Sankar, S., Svendrovski, A., Baral, S., & Oh, J. (2018) · Journal of Neuroimaging · doi:10.1111/jon.12553 · Cited by 129
Midaglia, L. S., Mulero, P., Montalbán, X., Graves, J., Hauser, S. L., Julian, L. J., Baker, M., Schadrack, J., Gossens, C., Scotland, A., et al. (2019) · Journal of Medical Internet Research · doi:10.2196/14863 · Cited by 128
The 2013 clinical course descriptors for multiple sclerosis: A clarification
Lublin, F. D., Coetzee, T., Cohen, J. A., Marrie, R. A., Thompson, A. J., & on behalf of the International Advisory Committee on Clinical Trials in MS (2020) · Neurology · doi:10.1212/wnl.0000000000009636 · Cited by 128
Lansley, J., Mataix‐Cols, D., Grau, M., Raduà, J., & Sastre‐Garriga, J. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.03.006 · Cited by 126
Early Relapses, Onset of Progression, and Late Outcome in Multiple Sclerosis
Scalfari, A., Neuhaus, A., Daumer, M., DeLuca, G. C., Muraro, P. A., & Ebers, G. C. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.599 · Cited by 124
Self-citationDalakas, M. C. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb27543.x · Cited by 121
Serafini, B., Rosicarelli, B., Veroni, C., Mazzola, G. A., & Aloisi, F. (2019) · Journal of Virology · doi:10.1128/jvi.00980-19 · Cited by 121
Singh, S., Dallenga, T., Winkler, A., Roemer, S., Maruschak, B., Siebert, H., Brück, W., & Stadelmann, C. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0831-8 · Cited by 118
Systemic inflammation induces axon injury during brain inflammation
Moreno, B., Jukes, J., Vergara‐Irigaray, N., Errea, O., Villoslada, P., Perry, V. H., & Newman, T. A. (2011) · Annals of Neurology · doi:10.1002/ana.22550 · Cited by 117
Dihydroorotate dehydrogenase inhibitors in anti-infective drug research
Boschi, D., Pippione, A. C., Sainas, S., & Lolli, M. L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111681 · Cited by 115
Giovannoni, G., Cutter, G., Sormani, M. P., Belachew, S., Hyde, R., Koendgen, H., Knappertz, V., Tomic, D., Leppert, D., Herndon, R., et al. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.01.007 · Cited by 114
Self-citationRemyelination and ageing: Reversing the ravages of time
Neumann, B., Segel, M., Chalut, K. J., & Franklin, R. J. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519884006 · Cited by 114
Axonal loss in the multiple sclerosis spinal cord revisited
Petrova, N., Carassiti, D., Altmann, D. R., Baker, D., & Schmierer, K. (2017) · Brain Pathology · doi:10.1111/bpa.12516 · Cited by 109
Uhthoff's phenomena in MS—clinical features and pathophysiology
Frohman, T. C., Davis, S. L., Beh, S. C., Greenberg, B. M., Remington, G. M., & Frohman, E. M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.98 · Cited by 108
Cree, B. A. C., Cutter, G., Wolinsky, J. S., Freedman, M. S., Comi, G., Giovannoni, G., Hartung, H.-P., Arnold, D., Kuhle, J., Block, V., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30347-1 · Cited by 108
Self-citationThe Pathologic Substrate of Magnetic Resonance Alterations in Multiple Sclerosis
Lassmann, H. (2008) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2008.06.005 · Cited by 106
Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome
Giannetti, P., Politis, M., Su, P., Turkheimer, F. E., Malik, O., Keihaninejad, S., Wu, K., Waldman, A., Reynolds, R., Nicholas, R., et al. (2015) · Brain · doi:10.1093/brain/awu331 · Cited by 106
In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis
Choi, I., Lee, P., Adany, P., Hughes, A. J., Belliston, S., Denney, D. R., & LYNCH, S. G. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517711568 · Cited by 106
Functional Connectivity in Multiple Sclerosis: Recent Findings and Future Directions
Tahedl, M., Levine, S. M., Greenlee, M. W., Weissert, R., & Schwarzbach, J. V. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00828 · Cited by 102
Datta, G., Colasanti, A., Rabiner, E. A., Gunn, R. N., Malik, O., Ciccarelli, O., Nicholas, R., Van Vlierberghe, E., Van Hecke, W., Searle, G., et al. (2017) · Brain · doi:10.1093/brain/awx228 · Cited by 99
Resolving the clinico-radiological paradox in multiple sclerosis
Chard, D., & Trip, S. A. (2017) · F1000Research · doi:10.12688/f1000research.11932.1 · Cited by 99
Reducing survey burden: feasibility and validity of PROMIS measures in multiple sclerosis
Senders, A., Hanes, D. A., BOURDETTE, D. N., Whitham, R. H., & Shinto, L. H. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458513517279 · Cited by 98
Multiple sclerosis: assessment of disability and disability scales
Thompson, A. J., & Hobart, J. C. (1998) · Journal of Neurology · doi:10.1007/s004150050204 · Cited by 94
The relationship of age with the clinical phenotype in multiple sclerosis
Scalfari, A., Lederer, C., Däumer, M., Nicholas, R. S., Ebers, G. C., & Muraro, P. A. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516630396 · Cited by 93
Self-citationPrediction of outcome in multiple sclerosis based on multivariate models
Runmarker, B., Andersson, C., Od�n, A., & Andersen, O. (1994) · Journal of Neurology · doi:10.1007/bf00920623 · Cited by 92
Tedeholm, H., Lycke, J., Skoog, B., Lisovskaja, V., Hillert, J. A., Dahle, C., Fagius, J., Fredrikson, S., Landtblom, A., Malmeström, C., et al. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512463764 · Cited by 92
Self-citationBrain Atrophy in Multiple Sclerosis
Sastre‐Garriga, J., Pareto, D., & Rovira, À. (2017) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2017.01.002 · Cited by 88
Gibiansky, E., Petry, C., Mercier, F., Guenther, A., Herman, A. E., Kappos, L., Hauser, S. L., Yamamoto, Y., Wang, Q., Model, F., et al. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14658 · Cited by 88
Jakimovski, D., Guan, Y., Ramanathan, M. K., Weinstock‐Guttman, B., & Zivadinov, R. (2019) · Neurodegenerative Disease Management · doi:10.2217/nmt-2018-0046 · Cited by 87
Neurogenesis in the chronic lesions of multiple sclerosis
Chang, A., Smith, M. C., Yin, X., Fox, R. J., Staugaitis, S. M., & Trapp, B. D. (2008) · Brain · doi:10.1093/brain/awn157 · Cited by 85
Longitudinal evidence for anterograde trans-synaptic degeneration after optic neuritis
Tur, C., Goodkin, O., Altmann, D. R., Jenkins, T. M., Miszkiel, K., Mirigliani, A., Fini, C., Gandini Wheeler-Kingshott, C. A. M., Thompson, A. J., Ciccarelli, O., et al. (2016) · Brain · doi:10.1093/brain/awv396 · Cited by 83
Bruton’s Tyrosine Kinase Inhibition Promotes Myelin Repair
Martin, E., Aigrot, M.-S., Grenningloh, R., Stankoff, B., Lubetzki, C., Boschert, U., & Zalc, B. (2019) · Brain Plasticity · doi:10.3233/bpl-200100 · Cited by 82
Self-citationImproving the Characterization of Radiologically Isolated Syndrome Suggestive of Multiple Sclerosis
De Stefano, N., Stromillo, M. L., Rossi, F., Battaglini, M., Giorgio, A., Portaccio, E., Hakiki, B., Malentacchi, G., Gasperini, C., Santangelo, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019452 · Cited by 81
Neuronal and Axonal Loss in Normal-Appearing Gray Matter and Subpial Lesions in Multiple Sclerosis
Klaver, R., Popescu, V., Voorn, P., Galis-de Graaf, Y., van der Valk, P., de Vries, H. E., Schenk, G. J., & Geurts, J. J. G. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000189 · Cited by 81
Self-citationNatalizumab treatment reduces microglial activation in the white matter of the MS brain
Sucksdorff, M., Tuisku, J., Matilainen, M., Vuorimaa, A., Smith, S., Keitilä, J., Rokka, J., Parkkola, R., Nylund, M., Rinne, J., et al. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000574 · Cited by 71
Self-citationOxidative Stress-Related Biomarkers in Multiple Sclerosis: A Review
Ibitoye, R. T., Kemp, K. C., Rice, C. M., Hares, K. M., Scolding, N. J., & Wilkins, A. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0097 · Cited by 71
Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data
Sastre-Garriga, J., Ingle, G. T., Rovaris, M., Téllez, N., Jasperse, B., Altmann, D. R., Benedetti, B., Stevenson, V. L., Cercignani, M., Leary, S. M., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000173061.12776.1f · Cited by 69
Teriflunomide slows BVL in relapsing MS
Radue, E. W., Sprenger, T., Gaetano, L., Mueller‐Lenke, N., Cavalier, S., Thangavelu, K., Panzara, M. A., Donaldson, J. E., Woodward, F. M., Wuerfel, J. T., et al. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000390 · Cited by 69
Self-citationCNS Remyelination and the Innate Immune System
McMurran, C. E., Jones, C. A., Fitzgerald, D. C., & Franklin, R. J. M. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00038 · Cited by 62
The Role of Wearable Devices in Multiple Sclerosis
Sparaco, M., Lavorgna, L., Conforti, R., Tedeschi, G., & Bonavita, S. (2018) · Multiple Sclerosis International · doi:10.1155/2018/7627643 · Cited by 60
Preactive Multiple Sclerosis Lesions Offer Novel Clues for Neuroprotective Therapeutic Strategies
M. van Noort, J., J. van den Elsen, P., van Horssen, J., J.G. Geurts, J., van der Valk, P., & Amor, S. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711794488566 · Cited by 59
A multiple course trial of desferrioxamine in chronic progressive multiple sclerosis.
Sg, L., Fonseca, T., & Sm, L. (2000) · PubMed · Cited by 57
Pathogenesis of Brain and Spinal Cord Atrophy in Multiple Sclerosis
Minagar, A., Toledo, E. G., Alexander, J. S., & Kelley, R. E. (2004) · Journal of Neuroimaging · doi:10.1177/1051228404266263 · Cited by 56
Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis
Baker, D., Pryce, G., Amor, S., Giovannoni, G., & Schmierer, K. (2018) · Brain · doi:10.1093/brain/awy239 · Cited by 56
Self-citationPatterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions
Elliott, C., Arnold, D. L., Chen, H., Ke, C., Zhu, L., Chang, I., Cahir-McFarland, E. D., Fisher, E., Zhu, B. Y., Gheuens, S., et al. (2020) · American Journal of Neuroradiology · doi:10.3174/ajnr.a6742 · Cited by 55
Smoking and worsening disability in multiple sclerosis: A meta-analysis
Heydarpour, P., Manouchehrinia, A., Beiki, O., Mousavi, S. E., Abdolalizadeh, A., Moradi‐Lakeh, M., & Sahraian, M. A. (2018) · Acta Neurologica Scandinavica · doi:10.1111/ane.12916 · Cited by 53
Toward Digital Self-monitoring of Multiple Sclerosis
Wendrich, K., van Oirschot, P., Martens, M. B., Heerings, M. A. P., Jongen, P. J., & Krabbenborg, L. (2019) · International Journal of MS Care · doi:10.7224/1537-2073.2018-083 · Cited by 50
Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging
Bezukladova, S., Tuisku, J., Matilainen, M., Vuorimaa, A., Nylund, M., Smith, S., Sucksdorff, M., Mohammadian, M., Saunavaara, V., Laaksonen, S., et al. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000691 · Cited by 49
Self-citationExercise and the brain in multiple sclerosis
Lozinski, B. M., & Yong, V. W. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520969099 · Cited by 46
Lipoic Acid and Other Antioxidants as Therapies for Multiple Sclerosis
Waslo, C. S., BOURDETTE, D. N., Gray, N. E., Wright, K. M., & Spain, R. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0566-1 · Cited by 40
Bodini, B., Poirion, E., Tonietto, M., Benoit, C., Palladino, R., Maillart, E., Portera, E., Battaglini, M., Bera, G., Kuhnast, B., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.231340 · Cited by 40
Self-citationEngl, C., Tiemann, L., Grahl, S., Bussas, M., Schmidt, P. J., Pongratz, V., Berthele, A., Beer, A.-K., Gaser, C., Kirschke, J. S., et al. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09841-0 · Cited by 40
Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism
Menzfeld, C., John, M., van Rossum, D., Regen, T., Scheffel, J., Jáňová, H., Götz, A. A., Ribes, S., Nau, R., Borisch, A., et al. (2015) · Glia · doi:10.1002/glia.22803 · Cited by 39
Imaging markers of multiple sclerosis prognosis
Louapre, C., Bodini, B., Lubetzki, C., Freeman, L. A., & Stankoff, B. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000456 · Cited by 39
Self-citationDesferrioxamine in chronic progressive Multiple Sclerosis: a pilot study
Lynch, S. G., Peters, K., & LeVine, S. M. (1996) · Multiple Sclerosis Journal · doi:10.1177/135245859600200306 · Cited by 33
Bonzano, L., Bove, M., Sormani, M. P., Stromillo, M. L., Giorgio, A., Amato, M. P., Tacchino, A., Mancardi, G., & Stefano, N. D. (2018) · European Journal of Neurology · doi:10.1111/ene.13789 · Cited by 31
Hyperbaric oxygen for multiple sclerosis
Kleijnen, J., & Knipschild, P. G. (1995) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1995.tb07017.x · Cited by 29
Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.
Hauser, S. L., Belachew, S. M., & Kappos, L. (2017) · PubMed · doi:10.1056/nejmc1702076 · Cited by 28
The pathophysiology of multiple sclerosis
Smith, K., McDonald, I., Miller, D., & Lassmann, H. (2006) · McAlpine's Multiple Sclerosis · doi:10.1016/b978-0-443-07271-0.50015-x · Cited by 26
Morrow, S. A., Rosehart, H., Şener, A., & Welk, B. K. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.11.028 · Cited by 25
Natalizumab differentially affects plasmablasts and B cells in multiple sclerosis
Henriksen, A. C., Ammitzbøll, C., Petersen, E. R., McWilliam, O. H., Sellebjerg, F. T., von Essen, M. R., & Christensen, J. R. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.102987 · Cited by 24
Ochoa-Ruiz, E., Díaz-Ruiz, R., Hernández-Vázquez, A. D. J., Ibarra‐González, I., Ortíz-Plata, A., Rembao, D., Ortega-Cuéllar, D., Viollet, B., Uribe‐Carvajal, S., Corella, J. A., et al. (2015) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2015.08.009 · Cited by 23
Pol, S. U., Sveinsson, M., Sudyn, M. L., Babek, N., Siebert, D., Bertolino, N., Modica, C. M., Preda, M., Schweser, F., & Zivadinov, R. (2018) · Journal of Neuroimaging · doi:10.1111/jon.12561 · Cited by 20
Kletzl, H., Gibiansky, E., Petry, C., Mercier, F., Guenther, A., Wang, Q., Model, F., Kappos, L., & Hauser, S. L. (2019) · Neurology · doi:10.1212/wnl.92.15_supplement.n4.001 · Cited by 17
Lassmann, H. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458512474091 · Cited by 15
The impact of social capital on patients with multiple sclerosis
Reyes, S., Suárez, S., Allen‐Philbey, K., Thomson, A., & Giovannoni, G. (2020) · Acta Neurologica Scandinavica · doi:10.1111/ane.13244 · Cited by 15
Self-citationBaird, J. F., Sasaki, J. E., Sandroff, B. M., Cutter, G., & Motl, R. W. (2020) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217320932341 · Cited by 13
Andreopoulou, G., Mercer, T. H., Enriquez, J. G., Justin, M., MacLeod, N., Harrison, E., Mahad, D., & van der Linden, M. L. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102630 · Cited by 10
Sleep in Patients With Neurologic Disease
Benjamin, S. E. (2020) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000887 · Cited by 9
The Yin and Yang of Inflammation in Multiple Sclerosis
Giovannoni, G. (2004) · Springer eBooks · doi:10.1007/978-88-470-2117-4_19 · Cited by 3
Self-citation
Cited by
Meier, S., Willemse, E. A. J., Schaedelin, S., Oechtering, J., Lorscheider, J., Melie-Garcia, L., Cagol, A., Barakovic, M., Galbusera, R., Subramaniam, S., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2022.5250 · Cited by 289
Self-citationTolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
Fox, R. J., Bar-Or, A., Traboulsee, A., Oreja-Guevara, C., Giovannoni, G., Vermersch, P., Syed, S., Li, Y., Vargas, W. S., Turner, T. J., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2415988 · Cited by 146
Self-citationCellular architecture of evolving neuroinflammatory lesions and multiple sclerosis pathology
Kukanja, P., Langseth, C. M., Rubio Rodríguez-Kirby, L. A., Agirre, E., Zheng, C., Raman, A., Yokota, C., Avenel, C., Tiklová, K., Guerreiro-Cacais, A. O., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.030 · Cited by 124
“87 The DA-glia detected within the EAE brain and their distribution throughout the spinal cord parenchyma, also in lesion-deprivedpeakcervicalandearlylumbarregions(Figure4), align with these concepts.”
BackgroundTSPO-detectable chronic active lesions predict disease progression in multiple sclerosis
Polvinen, E., Matilainen, M., Nylund, M., Sucksdorff, M., & Airas, L. M. (2023) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200133 · Cited by 36
Self-citationAssociation of serum neurofilament light with microglial activation in multiple sclerosis
Saraste, M., Matilainen, M., Vuorimaa, A., Laaksonen, S., Sucksdorff, M., Leppert, D., Kuhle, J., & Airas, L. (2023) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2023-331051 · Cited by 33
Self-citation
Metadata
- Authors
- Giovannoni, G., Popescu, V., Wuerfel, J., Hellwig, K., Iacobaeus, E., Jensen, M. B., García-Domínguez, J. M., Sousa, L., De Rossi, N., Hupperts, R., Fenu, G., Bodini, B., Kuusisto, H.-M., Stankoff, B., Lycke, J., Airas, L., Granziera, C., & Scalfari, A.
- Venue
- Therapeutic Advances in Neurological Disorders
- Publisher
- SAGE Publications
- Published
- 2022-01
- Volume
- 15
- Pages
- 17562864211066751-17562864211066751
- ISSN
- 1756-2856 (ISSN-L)
- 1756-2864
- OpenAlex
- W4226087203
- Cited by
- 271
- References
- 134
- FWCI
- 30.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.